500 related articles for article (PubMed ID: 33694102)
1. Role of TGF-β in pancreatic ductal adenocarcinoma progression and PD-L1 expression.
Hussain SM; Kansal RG; Alvarez MA; Hollingsworth TJ; Elahi A; Miranda-Carboni G; Hendrick LE; Pingili AK; Albritton LM; Dickson PV; Deneve JL; Yakoub D; Hayes DN; Kurosu M; Shibata D; Makowski L; Glazer ES
Cell Oncol (Dordr); 2021 Jun; 44(3):673-687. PubMed ID: 33694102
[TBL] [Abstract][Full Text] [Related]
2. TGF-β Alters the Proportion of Infiltrating Immune Cells in a Pancreatic Ductal Adenocarcinoma.
Trebska-McGowan K; Chaib M; Alvarez MA; Kansal R; Pingili AK; Shibata D; Makowski L; Glazer ES
J Gastrointest Surg; 2022 Jan; 26(1):113-121. PubMed ID: 34260016
[TBL] [Abstract][Full Text] [Related]
3. Tumor-associated macrophages promote pancreatic ductal adenocarcinoma progression by inducing epithelial-to-mesenchymal transition.
Xiong C; Zhu Y; Xue M; Jiang Y; Zhong Y; Jiang L; Shi M; Chen H
Aging (Albany NY); 2021 Jan; 13(3):3386-3404. PubMed ID: 33428605
[TBL] [Abstract][Full Text] [Related]
4. Single dual-specific anti-PD-L1/TGF-β antibody synergizes with chemotherapy as neoadjuvant treatment for pancreatic ductal adenocarcinoma: a preclinical experimental study.
Zhang H; Chen J; Bai J; Zhang J; Huang S; Zeng L; Zhou P; Shen Q; Yin T
Int J Surg; 2024 May; 110(5):2679-2691. PubMed ID: 38489548
[TBL] [Abstract][Full Text] [Related]
5. TGF-β Inhibitors in Metastatic Pancreatic Ductal Adenocarcinoma.
Alvarez MA; Freitas JP; Mazher Hussain S; Glazer ES
J Gastrointest Cancer; 2019 Jun; 50(2):207-213. PubMed ID: 30891677
[TBL] [Abstract][Full Text] [Related]
6. Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF-β signaling pathway.
Yin Z; Ma T; Huang B; Lin L; Zhou Y; Yan J; Zou Y; Chen S
J Exp Clin Cancer Res; 2019 Jul; 38(1):310. PubMed ID: 31307515
[TBL] [Abstract][Full Text] [Related]
7. Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic cancer.
Yin H; Pu N; Chen Q; Zhang J; Zhao G; Xu X; Wang D; Kuang T; Jin D; Lou W; Wu W
Cell Death Dis; 2021 Oct; 12(11):1033. PubMed ID: 34718325
[TBL] [Abstract][Full Text] [Related]
8. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma.
Daunke T; Beckinger S; Rahn S; Krüger S; Heckl S; Schäfer H; Wesch D; Pilarsky C; Eckstein M; Hartmann A; Röcken C; Wandmacher AM; Sebens S
Front Immunol; 2023; 14():1157397. PubMed ID: 37449210
[TBL] [Abstract][Full Text] [Related]
9. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
[TBL] [Abstract][Full Text] [Related]
10. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression.
Ijichi H; Chytil A; Gorska AE; Aakre ME; Fujitani Y; Fujitani S; Wright CV; Moses HL
Genes Dev; 2006 Nov; 20(22):3147-60. PubMed ID: 17114585
[TBL] [Abstract][Full Text] [Related]
11. The pancreatic cancer immune tumor microenvironment is negatively remodeled by gemcitabine while TGF-β receptor plus dual checkpoint inhibition maintains antitumor immune cells.
Rana M; Kansal R; Chaib M; Teng B; Morrrison M; Hayes DN; Stanfill AG; Shibata D; Carson JA; Makowski L; Glazer ES
Mol Carcinog; 2022 Jun; 61(6):549-557. PubMed ID: 35319799
[TBL] [Abstract][Full Text] [Related]
12. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer.
Kajiwara Y; Tazawa H; Yamada M; Kanaya N; Fushimi T; Kikuchi S; Kuroda S; Ohara T; Noma K; Yoshida R; Umeda Y; Urata Y; Kagawa S; Fujiwara T
Cancer Immunol Immunother; 2023 May; 72(5):1285-1300. PubMed ID: 36436021
[TBL] [Abstract][Full Text] [Related]
14. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
[TBL] [Abstract][Full Text] [Related]
15. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-α leads to poor pancreatic cancer prognosis.
Tsukamoto M; Imai K; Ishimoto T; Komohara Y; Yamashita YI; Nakagawa S; Umezaki N; Yamao T; Kitano Y; Miyata T; Arima K; Okabe H; Baba Y; Chikamoto A; Ishiko T; Hirota M; Baba H
Cancer Sci; 2019 Jan; 110(1):310-320. PubMed ID: 30426611
[TBL] [Abstract][Full Text] [Related]
17. Kindlin-2 induced by TGF-β signaling promotes pancreatic ductal adenocarcinoma progression through downregulation of transcriptional factor HOXB9.
Zhan J; Song J; Wang P; Chi X; Wang Y; Guo Y; Fang W; Zhang H
Cancer Lett; 2015 May; 361(1):75-85. PubMed ID: 25724625
[TBL] [Abstract][Full Text] [Related]
18. Statins abrogate gemcitabine-induced PD-L1 expression in pancreatic cancer-associated fibroblasts and cancer cells with improved therapeutic outcome.
Minz AP; Mohapatra D; Dutta M; Sethi M; Parida D; Mohapatra AP; Mishra S; Kar S; Sasmal PK; Senapati S
Cancer Immunol Immunother; 2023 Dec; 72(12):4261-4278. PubMed ID: 37926727
[TBL] [Abstract][Full Text] [Related]
19. HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer.
Zhou Y; Jin X; Yu H; Qin G; Pan P; Zhao J; Chen T; Liang X; Sun Y; Wang B; Ren D; Zhu S; Wu H
Theranostics; 2022; 12(5):2080-2094. PubMed ID: 35265200
[No Abstract] [Full Text] [Related]
20. GNG12 regulates PD-L1 expression by activating NF-κB signaling in pancreatic ductal adenocarcinoma.
Li J; Jin C; Zou C; Qiao X; Ma P; Hu D; Li W; Jin J; Jin X; Fan P
FEBS Open Bio; 2020 Feb; 10(2):278-287. PubMed ID: 31898405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
